Consensus and clinical practice guidelines in Latin America: Who, where, when and how

Campollo, Octavio; Román, Sonia

doi:10.1016/j.aohep.2019.03.001

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of a comprehensive surveillance system, a fragmented healthcare system, and a scarcity of research all contribute to this predicament [23]. Furthermore, there is a tendency to transfer data from other regions into local clinical practice guidelines (CPGs) to fill the gaps when it comes to indications for testing, treatment, and prevention measures without considering the host's and virus's genetics and environmental factors, which determine the clinical course of infection based on the population's predominant genotype, which in this case is HBV genotype H [28].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Virus Genotype H: Epidemiological, Molecular, and Clinical Characteristics in Mexico

Panduro,

Roman,

Laguna-Meraz

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

The hepatitis B virus (HBV), comprising of ten genotypes (A-J), has been a silent threat against humanity, constituting a public health problem worldwide. In 2016, the World Health Organization set forth an impressive initiative for the global elimination of viral hepatitis by 2030. As the target date approaches, many nations, particularly in the Latin American region, face challenges in designing and implementing their respective elimination plan. This review aimed to portray the state of knowledge about the epidemiological, molecular, and clinical characteristics of HBV genotype H (HBV/H), endemic to Mexico. PubMed, Scopus, Web of Science, and Google Scholar were searched to compile scientific literature over 50 years (1970–2022). A total of 91 articles were organized into thematic categories, addressing essential aspects such as epidemiological data, risk factors, HBV genotype distribution, HBV mixed infections, clinical characteristics, and vaccination. The prevalence and its associated 95% confidence interval (95% CI) were estimated using the Metafor package in R programming language (version 4.1.2). We provide insights into the strengths and weaknesses in diagnostics and prevention measures that explain the current epidemiological profile of HBV/H. Training, research, and awareness actions are required to control HBV infections in Mexico. These actions should contribute to creating more specific clinical practice guides according to the region’s characteristics. Mexico’s elimination plan for HBV will require teamwork among the government health administration, researchers, physicians, specialists, and civil society advocates to overcome this task jointly.

show abstract

Section: Introductionmentioning

confidence: 99%